Morning Biotech Lottery Winner $NBIX

I will be watching how trade progresses today in Neurocrine Biosciences. This morning they reported meeting the primary endpoint of their Phase III Kinect Trial of NBI-98854 (whatever the shit that is).

So far it is getting the fade treatment, the old cash out on the news look.

The biotech industry is still in the hot seat, but also heavily shorted by the retail crowd. I am running with the herd via BIS. Therefore I’m keeping my eyes on the horizon in case we’re all running toward an international border fortified with bouncing betty mines and artillery.